DAFTAR PUSTAKA

1. Lapeere H, Boone B, Schepper SD, Verhaeghe E, Gele MV, Ongenae K, et al. Hypomelanoses and hypermelanoses. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel DJ, Wolff K, eds. Fitzpatrick's dermatology in general medicine, 8th ed, vol 1. New York: Mc Graw Hill, 2012: p. 804 - 26.
2. Trout CR, Levine N, Chang MW. Disorders of pigmentation. In: Bolognia JL, Jorizzo JL, Rapini R, editor. Dermatology. 2nd ed, vol 1. London: Mosby, 2004: p. 975-1004.
3. Soepardiman L. Kelainan pigmen. In: Djuanda A, Hamzah M, Aisah S, editors. Ilmu penyakit kulit dan kelamin. 5th ed. Jakarta: FKUI, 2007: p. 289-99.
4. Rizal Y, Lestari S. Insidens melasma di Poli Kulit dan Kelamin RSUP Dr. M.Djamil Padang tahun 2001-2006. Media Dermato-Venereologica Indonesiana. 2008; 35: 56-9.
5. James WD, Berger TG, Elston DM. Disturbances of pigmentation. In: James WD, Berger TG, Elston DM, eds. Andrews' disease of the skin clinical dermatology. 11th ed. New York: WB Saunders Comp, 2011: p. 843-62.
6. Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. Journal of the American Academy Dermatology. 2006; 54: S272-81.
7. Pinto JM, Borges MDFM, Magalhaes GM. A review of melasma, part 1: Ethiopathogenic factors, clinical and histopathologic evaluations. Cosmetic Dermatology. 2006; Vol.19(11): 683-7.
8. Jimbow K, Jimbow M. Pigmentary disorders in oriental skin. Clinico Dermatology. 1989; 7(2): 11-27.

9. Taylor SC. Epidemiology of skin diseases in people of color. Highlighting Skin of Color. 2003; Vol.71: 271-275.
10. Sheth VM, Pandya AG. Melasma: A comprehensive update part I. Journal of the American Academy Dermatology. 2011; Vol.65(4): 689-697.
11. Shankar KDSR, Somani VK, Kohli M, Sharad J, Ganjoo A, Kandhari S, et al. A cross-sectional, multicentric clinico-epidemiological study of melasma in India. Dermatologic Therapy. 2014; 3: 71-81.
12. Goh CL, Dlova CN. A retrospective study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral center in Singapore. Singapore Medical Journal. 1999; 40(7): 455-8.
13. Almosuly IM, Butros RO. Clinical assessment of melasma in patients attending the Department of Dermatology and Venereology at Rizgary Teaching Hospital in Erbil City. Zanco Journal of Medical Sciences. 2010; Vol.14(2): 55-60.
14. Parsad D, Kumarasinge PW. Psycho-social implications of pigmentary disorders in Asia. Journal of Investigative Dermatology. 2006; Oct: 1-8.
15. Walker C. Skin disease and psychology: A multitude of links. In: Walker C dan Papadopoulos L, editors. Pshychodermatology the psychological impact of skin disorders. New York: Cambridge University Press, Cambridge, 2005; p. 1-14.
16. Doward LC, McKenna SP. Evolution of quality assessment. In: Rajagopalan R, Sheretz EF, Anderson TR, editors. Care management of skin disease. New York: Marcell-Dekker. 1998; p. 9-94.
17. Ali R, Aman S, Nadeem M, Kazmi AH. Quality of life in patients of melasma. Journal Pakistan of Dermatologists. 2013; 23(2): 143-148.

18. Pawaskar MD, Parikh P, Markowsky T, McMichael AJ, Feldman SR, Balkrishnan R. Melasma and its impact on health-related quality of life in Hispanic women. Journal of Dermatology Treatment. 2007; Vol.18(1): 5-9.

19. Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, et al. Development and validation of a health-related quality of life instrument for women with melasma. British Journal of Dermatology. 2003; 149: 572-577.

20. Steiner D, Feola C, Bialeski N, Silva FAM. Treatment of melasma: Systematic review. Surgical & Cosmetic Dermatology. 2009; 1(2): 87-94.

21. Shweta K, Khozema S, Meenu R, Anupama S, Singh SK, Neelima S. A systemic review on melasma: A review. International Journal of Current Bio Medical Sciences. 2011; 1(2): 63-8.

22. Cranenburgh OD, Prinsen CAC, Sprangers MAG, Spuls P, Korte JD. Health-related quality of life assessment in dermatologic practice: Relevance and application. Dermatologic Clinics. 2012; 30(2): 323-332.

23. Yazdanfar A, Hashemi B. Association of melasma with thyroid autoimmunity: A case-control study. Iranian Journal of Dermatology. 2010; Vol.13(2): 51-3.

24. Odom RB, James WD, Berger TG. Disturbances of pigmentation. In: James WD, Berger TG, Elston DM, eds. Andrew's diseases of the skin, 11th ed. Philadelphia: WB Saunders-Elsevier Company. 2011: p. 846-62.

25. Achar A, Rathi SK. Melasma: A clinico-epidemiological study of 312 cases. Indian Journal of Dermatology. 2011; 56(4): 380-2.

26. Dogra A, Dua A, Singh P. Thyroid and skin. Indian Journal of Dermatology. 2006; 51(2): 96-9.

27. Dogra A, Dua A. Cutaneous changes in hypotiroidism. Thyroid Research and Practice. 2006; Vol.3(2): 45-9.

28. Haritha S, Sampath K. Skin manifestation of hypothyroidism – a clinical study. Journal of Dental and Medical Sciences. 2013; Vol.7(2): 58-60.

29. Malek ZAA, Kadekaro AL. Human cutaneous pigmentation. Physiological Regulation of Human Cutaneous Pigmentation. 2010; 11: 81-100.

30. Solano F. Melanins: Skin pigments and much more types, structural models, biological functions, and formation routes. New Journal of Science. 2014; 6: 1-28.

31. Dentice M, Salvatore D. Deiodinase: The balance of thyroid hormone: Local impact of thyroid hormone inactivation. Journal of Endocrinology. 2011; 209(3): 273-82.

32. Safer JD. Thyroid hormone action on skin. Dermato-Endocrinology. 2011; 3(3): 211-5.

33. Paus R. Exploring the "thyroid-skin connection": Concepts, questions, and clinical relevance. Journal of Investigative Dermatology. 2010; 130: 7-10.

34. Bodo E, Kany B, Gaspar E, Knuver J, Kromminga A, Biro T, et al.. Thyroid-stimulating hormone, a novel, locally produced modulator of human epidermal functions, is regulated by thyrotropin-releasing hormone and thyroid hormones. Endocrinology. 2010; 151: 1633-42.

35. Zouboulis CC. The human skin as a hormone target and an endocrine gland. Hormones. 2004; 3(1): 9-26.

36. Jurado CC, Serrano LG, Ferreria MG, Costa C, Paramio JM, Aranda A. The thyroid hormone receptors as modulators of skin proliferation and inflammation. Journal of Biological Chemistry. 2011; 286(27): 24079-88.

37. Kasraee B. Depigmentation of brown Guinea pig skin by topical application of methimazole. The Journal of Investigative Dermatology 2002; 1: 205-7.

38. Mullin GE, Eastern JS. Cutaneous consequences of accelerated thyroid function. Cutis. 1986; 37: 109-114.

39. Kasumagic HE. Thyroid disease and the skin. Annals of Thyroid Research. 2014; 1(2): 27-31.

40. Park KC, Huh SY, Choi HR, Kim DS. Biology of melanogenesis and the search for hypopigmenting agents. Dermatologica Sinica. 2010; 28: 53-8.

41. Choi HI, Sohn KC, Hong DK, Lee Y, Kim CD, Yoon TJ, et al. Melanosom uptake is associated with the proliferation and differentiation of keratinocytes. Archives of Dermatological Research. 2014; 306: 59-66.

42. Videira IFS, Magina S, Moura DFL. Mechanism regulating melanogenesis. Anais Brasileiros de Dermatologia. 2013; 88(1): 76-83.

43. Ebanks JP, Koshoffer A, Wickett RR, Schwemberger S, Babcock G, Hakozaki T, et al. Epidermal keratinocytes from light vs. dark skin exhibit differential degradation of melanosomes. Journal of Investigative Dermatology. 2011; Vol.131: 1226-33.

44. Ebanks JP, Wickett RR, Boissy RE. Mechanism regulating skin pigmentation: The rise and fall of complexion coloration. International Journal of Molecular Sciences. 2009; 10: 4066-87.

45. Grando SA. Physiology of endocrine skin interrelations. Journal of the *American Academy* of *Dermatology*. 1993; 28: 981-92.

46. Kasraee B, Hugin A, Tran C, Sorg O, Saurat JH. Methimazole is an inhibitor of melanin synthesis in cultured B16 melanocytes. The Journal of Investigative Dermatology. 2004; 12: 1338-41.

47. Barrett EJ. The thyroid gland. In: Boron WF, Boulpaep EL, eds. Medical physiology. A cellular and mollecular approach. 1st ed. Philadelphia: Saunders, 2003: p. 1035-48.

48. Chiamolera MI, Wondisford FE. Minireview: Thyrotropin-releasing hormone and the thyroid hormone feedback mechanism. Endocrinology. 2009; 150(3): 1091-6.

49. Gaspar E, Nguyen-Thi KT, Hardenbicker C, Tiede S, Plate C, Bodo E, et al.. Thyrotropin-releasing hormone selectively stimulates human hair follicle pigmentation. Journal of Investigative Dermatolology. 2011; Vol. 131: 2368-77.

50. Slominski A. Neuroendocrine activity of melanocyte. Experimental *Dermatology*. 2009; 18(9): 760-3.

51. Tsygankova OM, Saavedra A, Rebhun JF, Quilliam LA, Meinkoth JL. Coordinated regulation of Rap1 and thyroid differentiation by cyclic AMP and protein kinase A. Molecular and Cellular Biology. 2001; Vol.21(6): 1921-9.

52. Zanni MSG, Campana R, Papa M, Ragazzini L, Monetti E, Trakal JJ. Cutaneous manifestation in hypothyroid patients. Clinica Universitaria Reina Fabiola. 2008; 2:1-4.

53. Antonini D, Sibilio A, Dentice M, Missero C. An intimate relationship between thyroid hormone and skin: Regulation of gene expression. Frontiers in Endocrinology. 2013; Vol.4(104): 1-9.

54. Sugimoto K, Mori K. Thyroid-stimulating hormone regulation and transcription in hypothyroidism. Influences and Treatments Intechopen. 2012; 15: 255-76.

55. Guarneri F. Ethiopathogenesis of melasma. Pigmentary Disorders. 2014; S1: 1-5.

56. Talaee R, Ghafarpasand I, Masror H. The relationship between melasma and disturbances in the serum level of thyroid hormones and indices. Medicine Journal. 2015; 2(2): 19-23.

57. Luthfi RJ, Fridmanis M, Misiunas AL, Pafume O, Gonzales EA, Villemur JA, et al.. Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma. Journal of Clinical Endocrinology & Metabolism. 1985; 61: 28-31.

58. Kiani A, Ahmari M, Rezvan FMR. Association of melasma with thyroid disorders: A case-control study. Iranian Journal of Dermatology. 2006; 9(2(36)): 154-8.

59. Niepomniszcze H, Amad H. Skin disorders and thyroid diseases. Journal of Endocrinological Investigation. 2001; 24(8): 628-38.

60. Kavya M. Melasma: A clinico-epidemiological study. International Journal of Basic and Applied Medical Sciences. 2014; Vol.4(2): 388-91.

61. Mogaddam MR, Alamdari MI, Maleki N, Ardabili NS, Abedkouhi S. Evaluation of autoimmune thyroid disease in melasma. Journal of Cosmetic Dermatology. 2015; 0: 1-5.

62. Taylor SC. Objective and subjective measures of melasma. Cosmetic Dermatology. 2007; Vol.20(2): 93-5.

63. Taylor S, Westerhof W, Im S, Lim J. Noninvasive techniques for the evaluation of skin color. Journal of the American Academy Dermatology. 2006; 54: S282-90.

64. Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P, et al.. Reliability assessment and validation of the melasma area and severity index (MASI) and a new modified MASI scoring method. Journal of the American Academy Dermatology. 2011; 64: 78-83.

65. Treesirichod A, Chansakulporn S, Wattanapan P. Correlation between skin color evaluation by skin color scale chart and narrowband reflectance spectrophotometer. Indian Journal of Dermatology. 2014; 59(4): 339-42.

66. Damevska K. New aspects of melasma. Serbian Journal of Dermatology and Venereology. 2014; 6(1): 5-18.

67. Handel AC, Miot LDB, Miot HA. Melasma: A clinical and epidemiological review. Anais Brasileiros de Dermatologia. 2014; 89(5): 771-82.

68. Werlinger KD, Guevara IL, Gonzales CM, Rincon ET, Caetano R, Haley Rw, et al.. Prevalence of self-diagnosed melasma among pre-menopausal Latino women in Dallas and Forth Worth Tex. Archives of Dermatology. 2007; 143: 424-5.

69. Sanchez MR. Cutaneous disease in Latinos. Dermatological Clinics. 2003; 21: 689-97.

70. Ishiy PS, Silva LR, Penha MA, Handel AC, Miot HA. Skin diseases reported by workers from the campus UNESP Rubiao Jr, Botucatu-SP (Brazil). Anais Brasileiros de Dermatologia. 2014; 89: 529-31.

71. Tomb RR, Nassar JS. Profile of skin diseases observed in a department of dermatology (1995-2000). Journal Medical Libanais. 2000; 48: 302-9.

72. Shenoi SD, Davis SV, Rao S, Rao G, Nair S. Dermatoses among paddy field workers – A descriptive, cross-sectional pilot study. Indian Journal of Dermatology Venereology and Leprology. 2005; 71: 254-8.

73. El-Essawi D, Musial JL, Hammad A, Lim HW. A survey of skin disease and skin-related issues in Arab Americans. Journal of the American Academy Dermatology. 2007; 56: 933-8.

74. Sivayathorn A. Melasma in orientals. Clinical Drug Investigation. 1995; 10(suppl 2): 34-40.

75. Febrianti T, Sudharmono A, Rata IGAK, Bernadette I. Epidemiologi melasma di Poliklinik Departemen Ilmu Kesehatan Kulit dan Kelamin RS dr. Cipto Mangunkusumo Jakarta tahun 2004. Perdoski [Internet]. 2004 [disitasi 30 April 2014]. Tersedia di: perdoski.org/index.php/public/information/mdvi-detai-content/86.

76. Park HY, Yaar M. Biology of melanocytes. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel DJ, Wolff K, eds. Fitzpatrick's dermatology in general medicine, 8th ed, vol 1. New York: Mc Graw Hill, 2012: p. 765-81.

77. Seiberg M. Keratinocyte-melanocyte interactions during melanosome transfer. European Society for Pigment Cell Research and the International Pigment Cell Society. 2001; 14: 236-242.

78. Eberle AN. Proopiomelanocortin and the melanocortin peptides. In: Eberle AN, Cone RD, eds. The melanotropins: chemistry, physiology and mechanism of actions. Basel: Karger Verlag. 1988: p.3-67.

79. Mastore M, Kohler L, Nappi AJ. Production and utilization of hydrogen peroxide associated with melanogenesis and tyrosinase-mediated oxidation of DOPA and dopamine. Federation of European Biochemical Societies Journal. 2005; 272: 2407-15.

80. Boissy RE. Melanosome transfer to and translocation in the keratinocyte. Experimental Dermatology. 2003; 12(suppl.2): 5-12.

81. Lee ES, Kom JH, Im S, Lee KB, Sohn S, Kang WH. Application of computerized image analysis in pigmentary skin disease. International Journal of Dermatology. 2001; 40: 45-9.

82. Hamed SH, Asaf SA, Amro B. Innovative non-invasive technique in skin pharmaceutics vs valid complements in cosmetic dermatology practice. Jordan Journal of Pharmaceuticals Sciences. 2011; Vol.4(3): 174-80.

83. Devpura S, Pattamadilok B, Syed ZU, Vemulapalli P, Henderson M, Rehse SJ. Critical comparison of diffuse reflectance spectroscopy and colorimetry as dermatological diagnostic tools for acanthosis nigricans: A chemometric approach. Biomedical Optics Express. 2011; Vol.2(6): 1664-73.

84. Jacques SL. Quick analysis of optical spectra to quantify epidermal melanin and papillary dermal blood content skin. J Biophotonics. 2015; 8(4): 309-16.

85. Chatterjee M, Vasudevan B. Recent advances in melasma. Pigment International. 2014; Vol.1(2): 70-80.

86. Galeano J, Jolivot R, Marzani F, Benezeth Y. Unmixing of human skin optical reflectance maps by non-negative matrix factorization algorithm. National Electronics and Computer Technology Center. 2012; 10(16): 1-13.

87. Hindritiani R. Melasma. In: Wasitaatmadja SM, editor. Pigmentasi kulit. Jakarta: Badan Penerbit FKUI; 2015. p. 114-26.

88. Nikolaou V, Stratigos AJ, Katsambas AD. Established treatments of skin hypermelanoses. Journal of Cosmetic Dermatology. 2006; 5: 303-8.

89. Ortonne JP, Bose SK. Pigmentation: dyschromia. In: Baran R, Maibach HI, editor. Textbook of cosmetic dermatology. 3rd ed. London: Taylor&Francis; 2005. p. 393-410.

90. Ortonne JP. Retinoid therapy of pigmentary disorders. Dermatologic Therapy. 2006; 19: 280-8.

91. Olumide YM, Akinkugbe AO, Altraide D, Mohammed T, Ahamefule M, Ayanlowo S, et al. Complications of chronic use of skin lightening cosmetics. International Journal of Dermatology. 2008; 47: 344-53.

92. Lynde CB, Kraft JN, Lynde CW. Topical treatment of melasma and postinflammatory hyperpigmentation. Skin Therapy Letter. 2007; 1-12.

93. Fisher AA. Leukoderma from bleaching creams containing 2% hydroquinone. Contact Dermatitis. 1982; 8(4): 272-3.

94. Mann RJ, Harman RRM. Nail staining due to hydroquinone skin-lightening creams. British Journal of Dermatology. 1983; 108: 363-5.

95. BPOM RI. Kosmetik mengandung bahan berbahaya dan zat warna yang dilarang. Jakarta: BPOM RI, 2003.

96. Rendon M, Cardona LM, Bussear EW, Benitez AL, Colon LE, Johnson LA. Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: A pilot study. Cutis. 2008; Vol.28: 372-8.

97. Szkudlinski MW, Fremont V, Bonin C, Weintraub BD. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Pysiological Review. 2002; Vol.82: 473-502.

98. Brownstein D. 59 diseases now linked to thyroid imbalance, millions affected. Newsmax Media. 2010; Vol.3(4): 1-8.

99. Slominski A. Neuroendocrine system of the skin. Dermatology. 2005; 211: 199-208.

100. Slominski A, Wortsman J, Kohn L, Ain KB, Venkataraman GM, Pisarchik A, et al.. Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. Journal of Investigative Dermatology. 2002; 119(6): 1449-55.

101. Burman KD, McKinley GL. Dermatologic aspects of thyroid disease. Clinical Dermatology. 2006; 24: 247-55.

102. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocrine Reviews. 2000; 21: 457-87.

103. Lee AY, Noh M. The regulation of epidermal melanogenesis via cAMP and/or PKC signaling pathways: Insight for the development of hypopigmenting agents. Archive of Pharmacal Research. 2013; 36: 792-801.

104. Braverman L, Wartofsky L. Thyroid function tests. In: National Endocrine and Metabolic Disease Information Service. U.S Department of Health and Human Services. 2010; NIH Publication No. 10-6284.

105. Tijn DA, Vijder JJM, Vulsma T. Role of throtropin-releasing hormone stimulation test in diagnosis of congenital central hypotiroidism in infants. Journal of *Clinical Endocrinology & Metabolism.* 2008; 93(2): 410-9.

106. Shankar K, Godse K, Aurangbadkar S, Lahiri K, Mysore V, Ganjoo A, et al.. Evidence-based treatment for melasma: Expert opinion and a review. Dermatologic Therapy. 2014; 4: 165-86.

107. Moncada B, Sanchez LKS, Alvarez BT, Cazares JPC, Ramirez JDM, Gonzalez FJ. Molecular structure and concentration of melanin in the stratum corneum of patients with melasma. Photodermatology, Photoimmunology & Photomedicine. 2009; 25: 159-60.

108. Malek J, Chedraoui A, Nikolic D, Baroutt N, Ghosn S, Abbas O. Successful treatment of hydroquinone-resistant melasma using topical methimazole. Dermatologic Therapy. 2013; Vol.26: 69-72.

109. Kim H, Choi HR, Kim DS, Park KC. Topical hypopigmenting agents for pigmentary disorders and their mechanisms of action. Annals of Dermatology. 2012; Vol.24(1): 1-6.

110. Roy G, Mugesh G. Bioinorganic chemistry in thyroid gland: Effect of antithyroid drugs on peroxidase-catalyzed oxidation and iodination reactions. Bioinorganic Chemistry and Applications. 2006; 0: 1-9.

111. Taieb A, Andre MC, Briganti S, Picardo M. Inhibitors and enhancers of melanogenesis. In: Riley PA, Borovansky J, editors. Melanin and melanosomes biosynthesis, biogenesis, physiological, and pathological function. Germany: Wiley-Blackwell, 2011: p. 117-65.

112. Kasraee B, Ardekani GHS, Parhizgar A, Handjani F, Omrani GR, Samani M, et al.. Safety topical methimazole for the treatment of melasma. Skin Pharmacology & Physiology. 2008; 21: 300-5.

113. Khani C, Hoffman C, Gropper C, Desai S. Topical methimazole for the treatment of moderate to severe melasma. American Osteopathic College of Dermatology Fall Meeting. 2014; 0: 96-101.

114. Madiyono B, Moeslichan S, Sastroasmoro S, Budiman I, Purwanto SH. Perkiraan besar sampel. In: Sastroasmoro S, Ismael S, editors. Dasar-dasar metodologi penelitian klinis. 3rd ed. Jakarta: Sagung Seto, 2010: p. 302-31.

115. Kumari T, Prasad A, Sinha KK, Bharti MLG, Satyam K. Age and specific thyroid hormone profile in euthyroid subjects. Journal of Biochemical Technology. 2015; 6(3): 1008-12.

116. Watanabe S. Facial dermal melanocytosis. Austin Journal of Dermatology. 2014; Vol.1(2): 1-6.

117. Tranggono RIS, Adityarini. Cosmeceuticals for Asian who are living in the tropics. Journal of Applied Cosmetology 2010; 28: 71-86.

118. Umborowati MA, Rahmadewi. Studi Retrospektif: Diagnosis dan Terapi Pasien Melasma. *Berkala* Ilmu Kesehatan Kulit dan Kelamin. 2014; Vol.26(1): 56-63.

119. Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida AR, et al.. Validation of a melasma quality of life questionnaire for Brazillian Portuguese language: The MelasQol-BP study and improvement of QoL of melasma patients after triple combination therapy. British Journal of Dermatology. 2006; 156: 13-20.

120. Verma K, Kumre K, Sharma H, Singh U. A study of various etiological factors in the causation of melasma. International Journal of Comparative Education and Development. 2015; 1(1): 28-32.

121. Damevska K. New aspects of melasma. Serbian Journal of Dermatology & Venereology. 2014; 6: 5–18.

122. Tamega AA, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. Journal of European Academy Dermatology & Venereology. 2013; 27: 151-6.

123. Kaplan LA, Evans L, Monk C. Effects of mothers' prenatal psychiatric status and postnatal caregiving on infant biobehavioral regulation: Can prenatal programming be modified?. Early Human Development. 2007;84(4):249–56.

124. Mimura C, Griffiths P. A Japanese version of the perceived stress scale: Translation and preliminary test. International Joournal of Neuronal System. 2004; 41: 379 – 85.

125. Cui S, Li Y, Lu H, Gao XH, Wei H, Chen HD. Morphological relationship between nerve fibers and melanocytes in the epidermis of melasma. Clinical Pediatric Dermatology. 2016; Vol.2(12): 1 – 4.

126. Parsad D, Kumarasinge PW. Psycho-social implications of pigmentary disorders in Asia. Journal of Investagative Dermatology. 2006; Oct: 1-8.

127. Walker C. Skin disease and psychology: a multitude of links. In: Walker C dan Papadopoulos L, editors. Pshychodermatology the psychological impact of skin disorders. New York: Cambridge University Press, Cambridge, 2005; p. 1-14.